Get notified when RZLT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRezolute announces Phase 3 sunRIZE study results via oral presentation
Filed May 4, 2026 · Period ending May 1, 2026 · ~1 min read
Key Changes
-
high
Company disclosed results from its Phase 3 sunRIZE clinical trial through an oral presentation on May 1, 2026. Phase 3 trials are pivotal studies that determine drug approval eligibility and market potential.
Item 7.01 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade RZLT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify